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Abstract
Background This systematic literature review aimed to
evaluate and summarize the existing evidence on resource
use and costs associated with the diagnosis and treatment
of head and neck cancer (HNC) in adult patients, to better
understand the currently available data. The costs associ-
ated with HNC are complex, as the disease involves
multiple sites, and treatment may require a multidisci-
plinary medical team and different treatment modalities.
Methods Databases (MEDLINE and Embase) were
searched to identify studies published in English between
October 2003 and October 2013 analyzing the economics
of HNC in adult patients. Additional relevant publications
were identified through manual searches of abstracts from
recent conference proceedings.
Results Of 606 studies initially identified, 77 met the
inclusion criteria and were evaluated in the assessment.
Most included studies were conducted in the USA. The
vast majority of studies assessed direct costs of HNC, such
as those associated with diagnosis and screening, radio-
therapy, chemotherapy, surgery, side effects of treatment,
and follow-up care. The costs of treatment far exceeded
those for other aspects of care. There was considerable
heterogeneity in the reporting of economic outcomes in the
included studies; truly comparable cost data were sparse in
the literature. Based on these limited data, in the US costs
associated with systemic therapy were greater than costs
for surgery or radiotherapy. However, this trend was not
seen in Europe, where surgery incurred a higher cost than
radiotherapy with or without chemotherapy.
Conclusions Most studies investigating the direct
healthcare costs of HNC have utilized US databases of
claims to public and private payers. Data from these studies
suggested that costs generally are higher for HNC patients
with recurrent and/or metastatic disease, for patients
undergoing surgery, and for those patients insured by pri-
vate payers. Further work is needed, particularly in Europe
and other regions outside the USA; prospective studies
assessing the cost associated with HNC would allow for
more systematic comparison of costs, and would provide
valuable economic information to payers, providers, and
patients
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Key Points for Decision Makers
Head and neck cancer (HNC) is the sixth most
common malignancy globally, and poses a
substantial economic burden to payers, healthcare
systems, and patients. Costs associated with HNC are
driven by complex treatment pathways and the need
for involvement of several medical specialties.
Studies published from 2003 to 2013 mainly
examined direct costs of HNC, using data for the
USA. Few reports were available in the literature
describing indirect costs of the disease. Direct costs
of treatment appeared to be the main driver of costs
of HNC. In comparison, costs associated with
diagnosis, treatment-related side effects, or follow-
up care were minimal.
Considerable variation among studies regarding the
specific type of HNC within the patient population,
data sources, costing years, and healthcare systems
made meaningful comparisons challenging given the
available evidence. Prospective studies, such as
patient registries or trials with economic endpoints,
are needed to facilitate a systematic evaluation of the




Head and neck cancer (HNC) encompasses neoplasms
found in the oral cavity, pharynx, larynx, sinuses, and
salivary gland, and is common throughout the world. The
collective group of HNC, though heterogeneous in loca-
tion, most often arises in the squamous cells of epithelial
surfaces, and is often referred to as squamous cell carci-
noma (SCC) of the head and neck (SCCHN).
1.2 Epidemiology
Head and neck cancer is the sixth most common cancer
worldwide [1], and in 2013, 2.5 % of new cancer diagnoses
in the USA were estimated to be HNC [2]. Based on
recently released data for Europe from the World Health
Organization, the age-standardized incidence rate for HNC
varies from 3.5 per 100,000 in Cyprus to 23.0 per 100,000
in Hungary. Within the five most populous European
countries [EU5: UK, Italy, Germany, France, and Spain],
the range is much smaller, from 7.7 per 100,000 in Italy to
13.9 per 100,000 in France [3]. HNC incidence has
remained relatively stable over the past 10 years, and risk
factors for its occurrence have been fairly well established.
Notably, tobacco and alcohol use are associated with
higher HNC risk. The role of infection with human papil-
lomavirus (HPV) is less clear, although such infection
appears to be more commonly associated with oropharyn-
geal cancer, and possibly associated with better prognosis
compared with other factors [4, 5].
1.3 Management
While HNC incidence has remained stable, treatment and
patient management have become more complex, often
requiring a multidisciplinary team of oncologists, surgeons,
radiation therapists, nutritionists, pharmacists, and speech
therapists. In North American and European clinical
practice, patients with early stage HNC (approximately
one-third of those presenting with HNC) typically tend to
receive a single main treatment modality: radiotherapy or
surgery [6, 7]. The majority of patients (approximately
50 %), who are diagnosed with locally advanced HNC, are
typically treated with a combination of treatment modali-
ties including concurrent radiotherapy and chemotherapy
[concurrent chemoradiation therapy (CRT)], with surgery
if indicated [6]. The remaining patients (about one-fifth),
who present with metastatic disease, are usually treated
with palliative chemotherapy [6].
Depending on HNC severity and progression, the goal of
HNC therapy is either cure or palliation. However, a sig-
nificant amount of rehabilitation and supportive therapies
are also required for and concomitantly administered to
HNC patients to maintain or restore patients’ normal
function and activities. Reconstructive surgery and pros-
theses are important means of rehabilitation. Multidisci-
plinary rehabilitation also can take the form of nutritional
support, dietary counseling, and speech therapy. Addi-
tionally, follow-up care and surveillance are important, as
significant morbidity and mortality in this patient group are
associated with recurrent disease, rather than metastatic
disease as is more common in other oncologic indications
[6]. These multifaceted treatment approaches (of primary
and supportive regimens) have improved health-related
quality of life, morbidity, and mortality [8].
1.4 Research Objective
The past decade has seen substantial changes in the treat-
ment of HNC, with approval of new agents for systemic
therapy, and more widespread application of advancements
such as robotic surgery and intensity-modulated radio-
therapy (IMRT). While these measures frequently reduce
treatment-related toxicity and morbidity, they also may
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contribute to additional costs of treatment. This review
sought to examine the reported healthcare costs and
resource use associated with diagnosis, treatment, and
follow-up care for HNC. Admittedly, such a review is
made difficult by (1) the heterogeneity of HNC sites; (2)
the multidisciplinary nature of the healthcare provider team
and the heterogeneity of treatment that they administer; as
well as (3) practice pattern differences across geographic
regions. However, with these issues recognized, the
research was undertaken to gain a better understanding of
the economics associated with current medical practice in
HNC. This information can inform the multiple stake-
holders—patients, providers, payers, and health technology
assessment authorities—who are interested in the eco-
nomic burden of HNC and the positive or negative impacts
on that burden associated with current and future health-
care technologies and services. As such, this review can
serve as the new baseline for future comparative research.
2 Methods
A search of the medical literature was conducted in
MEDLINE (via PubMed) and Embase to identify relevant
English-language publications describing the economic
burden of HNC. The search identified publications using
specific keywords related to ‘‘head and neck, oropharyn-
geal or laryngeal’’ and other HNC sites and ‘‘cancer’’, and
those related to relevant economic outcomes, including
‘‘cost, resource utilization, economic or work loss’’. Key-
words had to be located in the title or abstract of full-length
publications, and studies had to be conducted in humans
and published within the 10 years preceding the search
(i.e., October 2003 to October 2013). Articles were inclu-
ded if they reported on overall costs or resource utilization
relating to screening and diagnostic procedures, interven-
tions and treatments, side effects/symptoms of treatment
(i.e., complications from surgery), or follow-up care in an
adult population of patients with HNC. Articles were
excluded if they did not report on economic outcomes for
HNC or for an adult population. Articles were also exclu-
ded if the costs described were not directly derived from
research original to the published work. Narrative (non-
systematic) reviews; genetic, cellular, or molecular studies;
case reports; case series; and conference abstracts pub-
lished prior to 2012 were also excluded.
The MEDLINE and Embase searches yielded 833
abstracts (323 from MEDLINE and 510 from Embase),
with some overlap between the two databases. After
removing the duplicate articles indexed on both MEDLINE
and Embase, there were 606 unique publications. The
abstracts identified by the search were manually reviewed
by a single researcher, with those abstracts that did not
meet any exclusion criteria examined as full-text publica-
tions. A total of 169 abstracts were selected for full-text
review. The full-text articles were assessed by two inde-
pendent investigators for eligibility for inclusion using the
same inclusion and exclusion criteria applied during
abstract screening. Any disagreements between the two
reviewers were resolved by a third independent reviewer.
Conference proceedings [American Head and Neck Society
(AHNS), American Society for Clinical Oncology
(ASCO), European Head and Neck Society (EHNS),
European Society for Medical Oncology (ESMO), and
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR)] from the past 2 years (i.e., 2012
and 2013) were also examined to identify relevant abstracts
for inclusion.
Articles were included in the final review if they did not
meet any of the exclusion criteria during full-text review.
Seventy-five articles, including nine abstracts selected from
conference proceedings, describing the economic burden of
HNC were identified for inclusion in the systematic liter-
ature review [9–82]. The 103 full-text articles that were
excluded were ineligible for the review because of their
publication date (n = 23), study design (n = 6), patient
population (n = 14), or outcomes reported (n = 60). A
single researcher evaluated the level of evidence for each
study using criteria from the University of Oxford’s Centre
for Evidence-Based Medicine (CEBM) Levels of Evidence
1 guidelines (2009) [83, 84]. CEBM ratings were only
given to peer-reviewed literature published in MEDLINE
and Embase. Overall, the quality of the identified literature
was relatively poor; all studies received a CEBM rating of
either 3b or 4. A summary of the full systematic literature
search strategy is presented in Fig. 1.
3 Results
3.1 Societal Costs of Head and Neck Cancer (HNC)
The full societal burden of HNC consists of the substantial
direct medical expenditures associated with the disease, but
also incorporates indirect costs, such as reduced workforce
participation and premature mortality, and the resultant
loss of productivity. To accurately analyze the societal cost
of this disease, economic evaluations of HNC must incor-
porate both direct and indirect costs. In the current review,
no such studies met the inclusion criteria; however, a few
recent publications provided context for the societal burden
of HNC.
In the USA and France, direct and indirect costs con-
tributed similarly to the overall societal cost of HNC, with
direct costs slightly higher than indirect costs in both
countries. National US expenditures in 2010 were
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calculated by combining 2010 cancer prevalence by cancer
site and phase of care with annualized expenditures asso-
ciated with cancer care in 2010 dollars. This estimate of
direct medical costs for HNC totaled US$3.64 billion in
2010 [85]. Similarly, a study assessing earnings lost as a
measure of productivity found that in 2010, the value of
lost productivity due to HNC was US$3.4 billion. Based on
projected growth and aging of the US population, pro-
ductivity costs will increase if cancer mortality rates are
constant in the future [86]. In addition, a French study
examining the ‘‘social’’ burden of laryngeal cancer attrib-
utable to occupational exposure to asbestos reported that
direct costs for this condition ranged from €35.3 million to
57.6 million, while indirect costs were €17.5 million to
34.9 million (2010 €) [87].
3.2 Total Direct Medical Costs of HNC
The direct medical costs of HNC have been assessed in 12
studies. Most (nine of 12) have used commercial or pub-
lically available US databases of administrative claims [9,
20, 34, 38, 41, 50, 54, 55, 78], with one each using the
Hospital Episode Statistic (HES) database in the UK [37],
hospital records from five Dutch university hospitals [69],
or a regional cancer center in Brazil [51]. Time horizons,
databases, demographic and disease subpopulations, and
costing years have ranged widely, hindering comparisons.
However, each economic snapshot taken from a different
angle shows that HNC presents high direct costs to payers.
3.3 Per-Patient Direct Medical Costs
3.3.1 Excess Cost Approach
In the US, most efforts to calculate the per-patient direct
medical costs of HNC have taken an excess cost approach,
with the difference between HNC patients and controls
without HNC representing the cost of the disease. Studies
reporting per-patient direct medical costs are summarized
in Table 1. Broadly comparable data are highlighted in this
table; for the sake of brevity and ease of use, not all
available data are presented in the tables.
Five-year excess costs were calculated by two studies
using Medicare claims linked to data from the Surveil-
lance, Epidemiology, and End Results (SEER) program of
the National Cancer Institute from different time periods:
patients newly diagnosed with SCCHN in a SEER registry
between 1991 and 1993 [41], and those whose first diag-
nosis of a primary tumor of the head and neck occurred
between 1995 and 2005 [78]. Using a costing year of 1998
US dollars (US$), patients in the earlier study incurred an
average of US$25,542 more than matched controls, with
mean Medicare costs of US$48,847 per patient (US$53,741
for those with distant metastases, US$58,387 with regional
spread, US$42,698 with local disease, US$37,434 with
in situ disease) [41]. In the later study, which used a costing
year of 2010 US$ and excluded prescription drugs, patients
incurred 5-year costs of US$34,489 more than matched
controls, with mean costs to Medicare of US$79,165 per
patient [78]. All patients in both studies were elderly, as
Medicare is the program that insures Americans over the
age of 65 years. While for some conditions this might limit
generalizability, HNC is diagnosed in the USA at a mean
age of 62 [88, 89], and thus a large percentage of the
disease population would be expected to be insured by
Medicare.
Two other recent studies using excess cost approaches
with data sources that included some patients insured by
Medicare examined different patient subgroups, limiting
comparisons. Both analyzed data from a commercial
database and the Medicare database, with one adding data
from other sources, including Medicaid, the program
designed to insure the poor and disabled. Kim Le et al.
[38], using commercial and Medicare data, calculated a
6-month adjusted cost to public and private US payers of
US$60,414 for metastatic and US$21,141 for recurrent
disease (2008 US$). Most of the incremental cost stemmed
from outpatient visits, approximately a third from inpatient
Fig. 1 Systematic search and screening flow chart. AHNS American
Head and Neck Society, ASCO American Society for Clinical
Oncology, EHNS European Head and Neck Society, ESMO European
Society for Medical Oncology, ISPOR International Society for
Pharmacoeconomics and Outcomes Research
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costs, and 11–13 % from drug cost. Patients with both
metastatic and recurrent disease had high use of supportive
care [38]. Jacobson et al. [34] reported 1-year costs of
US$71,151 for commercially insured patients, US$35,890
for those insured by Medicare, and US$44,541 for those
insured by Medicaid (2009 US$).
Three other studies in the USA used commercial dat-
abases to examine cost of illness in specific subgroups
defined by adverse reaction to drug treatment. Pike et al.
[50] looked at a small sample (n = 27) of patients who had
chemotherapy-associated peripheral neuropathy, calculat-
ing that those with HNC incurred US$36,660 more
annually to a commercial payer than matched controls
without peripheral neuropathy (2006 US$). Outpatient
treatment accounted for the largest part of these costs.
Reveles et al. [55] compared cohorts of patients before and
after approval of cetuximab in the USA in 2006 (although
it was approved specifically for HNC in 2011 [90]), finding
no significant differences in total costs to a commercial
payer (US$110,099 pre-cetuximab, US$111,156 post-ce-
tuximab) [costing year not reported (NR)]. Treatment costs
constituted nearly 90 % of these median totals, chiefly
because of outpatient costs and radiation [55]. The cost to a
payer of dermatologic reactions to cetuximab was assessed
Table 1 Per-patient burden of illness of head and neck cancer








USA Total 5-years costs 2010 US$79,165
Total 5-year costs for controls US$44,676
Jacobson et al. [34] USA Annual healthcare costs for commercially insured patients 2009 US$71,151
Annual healthcare costs for Medicare patients US$35,890
Annual healthcare costs for Medicaid patients US$44,541
Kim Le et al. [38] USA Total costs for metastatic cancer over 6 months 2008 US$65,412
Total costs for metastatic cancer controls over 6 months US$3,168
Total costs for recurrent locally advanced cancer over 6 months US$25,837
Total costs for recurrent locally advanced cancer controls over
6 months
US$2,752
Lang et al. [41] USA Mean Medicare payments 1998 US$48,847
Mean Medicare payments for controls US$23,305
Mean Medicare payments for distant cancer US$53,741
Mean Medicare payments for regional cancer US$58,387
Mean Medicare payments for local cancer US$42,698
Mean Medicare payments for in situ cancer US$37,434
Ray et al. [54] USA Mean monthly total healthcare costs for patients with dermatologic
side effect
2010 US$12,539
Mean monthly total healthcare costs for patients without dermatologic
side effect
US$9,684
Reveles et al. [55] USA Median total direct cost pre-cetuximab approval NR US$110,099
Median total direct cost post-cetuximab approval US$111,156
Attributable cost approach
Europe
Kim et al. [37] UK Mean annual postoperative healthcare utilization 2008–2009 £23,212
USA
Amonkar et al. [9] USA Mean annual healthcare costs 2008 US$34,450
Coughlan and Frick
[20]
USA Mean cost per case (condition approach) 2008 US$14,573
Mean cost per case (attributable approach) US$4,788
Rest of world
Pinto and Uga [51] Brazil Mean total cost of treatment for laryngeal cancer over 6 years 2006 R$37,529
Mean total cost of treatment for laryngeal cancer for the first year of
treatment
R$27,667
£ Great Britain pounds, NR not reported, R$ Brazilian reais, US$ US dollars
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by Ray et al. [54], who reported that among 971 HNC
patients given cetuximab, the 333 who had an adverse
reaction had average monthly healthcare costs of
US$12,539, compared with US$9,684 for patients with no
adverse reaction (2010 US$). The difference largely
resulted from additional hospitalization costs among
patients with reactions.
3.3.2 Attributable Cost Approach
Attributable costs, those that are directly coded to HNC,
have been assessed in a variety of databases. These studies
encompass two in the USA [9, 20] and one each in the UK
[37], Brazil [51], and the Netherlands [69]. In the USA,
annual attributable costs to a payer may range from
US$5–35,000, depending on the way the population is
defined. The high end of this range was estimated by
Amonkar et al. [9], who identified 1,104 commercially
insured patients in a claims database who were undergoing
surgical resection for HNC in the mid-2000s. These
patients were estimated to incur a mean total healthcare
cost per patient of US$34,450 annually (2008 US$).
Another analysis of US costs of HNC in commercial or
Medicare data found far lower costs, possibly because
patients identified by the earlier study were undergoing
surgery and incurring inpatient costs. This second analysis,
which used data from the Medical Expenditure Panel
Survey (MEPS), calculated attributable costs of HNC of
US$4,788 per case per year, largely to private payers. In
contrast with the previous study, outpatient visits tended to
drive these (correspondingly lower) costs [20]. However,
only 120 patients with this cancer could be identified in the
MEPS, and only 103 with events attributable to HCN,
underscoring the authors’ recommendations to use the
results of the different costing approaches as a range (thus
approximately US$5–15,000 per patient per year) rather
than precise point estimates [20].
The authors of this MEPS study also took a ‘‘condition
approach’’ to calculating direct medical costs, pooling
consolidated year files and condition files to estimate
healthcare utilization and expenditures in patients with this
cancer. This ‘‘condition approach’’ yielded a higher annual
cost of US$14,573 per case, with most costs associated
with inpatient care and notably higher than the results of
the attributable cost approach in which costs stemmed from
outpatient care. Outside the USA, data from five university
hospitals in the Netherlands were examined for patients
with laryngeal cancer; total mean costs per patient from
diagnosis through 1-year follow-up ranged from €8,232 to
€24,290, with increasing cost associated with more
advanced disease [69]. A Brazilian analysis of the costs of
laryngeal cancer in patients with a history of smoking
found that the mean total cost per patient over a 6-year
follow-up post-diagnosis was 37,529 Brazilian reais (R$).
The mean cost for the first year of treatment alone was
R$27,667 (2006 R$); the main drivers of cost were radio-
therapy and hospitalization [51]. Similarly, in the UK, Kim
et al. [37] used the HES database linked to mortality
records, and found that during the 5 years following
resection, HNC patients cost the National Health Service
(NHS) 23,212 Great Britain pounds (£) (2008–2009 £) per
patient. Nearly all of this cost (£19,778) was incurred
during the first year after resection, serving as a reminder
of why it is not possible to multiply annual costs of illness
by five to compare them to 5-year totals.
3.4 Overall Direct Medical Costs
Overall direct medical costs of HNC were estimated by
three studies: one in the UK using the HES database linked
to mortality data [37], one in the US using linked SEER–
Medicare data [78], and another US study using the MEPS
database [20]. In the UK, Kim et al. [37] examined data
from 11,403 patients after resection for HNC and estimated
that the cost to the NHS totaled £255.5 million over a
possible 5-year follow-up (2008–2009 £). The study by
Hollenbeak et al. [78] of linked SEER–Medicare data of an
elderly HNC cohort (n = 10,711) reported that, over
5 years, excess costs to Medicare of HNC care would total
US$369 million (2010 US$) compared with a matched
cohort of patients without HNC. Using the MEPS database,
Coughlan and Frick [20] took both an attributable and a
condition costing approach (described above) to generate a
range of estimates. With the condition approach, national
yearly expenditures in the USA totaled US$16.47 billion
(2008 US$). Attributable costs yielded annual expenditures
for all HNC-associated events of US$8.49 billion,
although, as noted above, only 120 respondents to the
MEPS survey had HNC, and only 103 had events attrib-
utable to the cancer.
3.5 Cost Analyses: Diagnostic Methods
Despite the technology and medical strategies involved in
diagnosis, the cost of this phase of care is eclipsed by that
of the treatment phase. In the US database study described
above, Reveles et al. [55] used commercial insurance
claims to compare the costs of each component of care,
finding that prior to the approval of cetuximab in the USA
in 2006 (it was specifically approved for HNC in 2011), the
diagnosis phase cost US$5,053 per patient, significantly
less than after cetuximab’s approval (US$6,860, costing
year NR). Cetuximab would be expected to raise the cost of
the diagnosis phase in another cancer indication, metastatic
colorectal cancer, as patients with this cancer receive
companion diagnostic testing (for K-ras mutation) for
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eligibility to take the drug. However, companion diagnostic
testing is not required for use of cetuximab in HNC.
Therefore, a post-cetuximab rise in diagnostic costs in
HNC could simply result from a rise in diagnosis costs over
time rather than a specific effect of cetuximab [90].
In the current review, six studies analyzed the costs of
diagnostic approaches to HNC. In Canada, Australia, and
the Netherlands, three studies suggested that combined
positron emission tomography (PET)/computed tomogra-
phy (CT) approaches yielded economic benefits when used
to assess metastatic spread and nodal response [40, 53, 68].
Two studies examined the use of telemedicine to facilitate
meetings with specialist physicians, finding that this
approach saved costs in Sweden and Scotland [24, 64].
A Dutch study assessed the cost of including a chest CT
scan in the initial tumor staging of patients with oral SCC
[35].
3.5.1 Imaging
Positron emission tomography/computed tomography
imaging, a diagnostic modality that has improved diag-
nostic accuracy and thus grown in importance over the last
decade [91, 92], was found to provide economic benefits in
three studies, and to present an acceptable cost-benefit
screening option in a fourth study [35, 40, 53, 68].
In a chart review in Canada and a cost-minimization
analysis in Australia, the cost of PET/CT to the health
service was offset by reducing additional procedures or
treatments. Using charts of 76 patients with advanced
disease in Alberta, Canada, Kurien et al. [40] calculated
that diagnostic workup using PET/CT cost 722 Canadian
dollars (C$), versus only C$450 for a workup without it
(costing year 2008–2009 C$ for examinations, 2005–2006
C$ for treatment). However, the patients whose cancer
would only have been identified as metastatic using PET/
CT could be treated with palliation, reducing the cost of
treatment in this group by nearly C$200,000 and sparing
the patients unnecessary treatments. The Australian cost-
minimization analysis of a prospective study found that
assessing nodal response with modalities incorporating
PET avoided the need for many neck dissections. The
strategy of using PET only for patients found (initially by
CT) to have an incomplete response incurred the lowest
costs to the Australian health service [2,111 Australian
dollars (A$) vs. A$16,502 for planned neck dissection and
A$8,014 for CT alone (2008–2009 A$)] [53].
Two Dutch studies also found economic benefits of
PET/CT. A prospective study of 80 patients at high risk
for distant metastases found that CT plus 18F-fluorode-
oxyglucose (FDG) PET was a dominant strategy for pre-
treatment screening over either imaging modality alone,
meaning that it was both more effective (sensitive) and
saved costs (€203–604, costing year NR) [68]. Another
analysis of patients with oral SCC found that including a
chest CT in the initial screening workup cost €8,214
(costing year NR) for each patient benefitting from the
chest CT scan (each pulmonary malignancy identified).
This cost was considered by the authors to align with
screening and diagnosis costs in the Netherlands for sev-
eral other types of cancer, such as breast (€8,134) and
cervical cancer (€10,270) [35].
3.5.2 Telemedicine
Costs of diagnosis include not just tools of diagnosis but
also the need to bring together patients and specialists, and
two studies found that telemedicine saved costs over
meeting in person [24, 64]. A survey study of 84 HNC
patients in Sweden found that while face-to-face meetings
for either diagnosis or treatment cost 2,267 Swedish kronor
(SEK), meetings conducted by telemedicine cost
SEK2,036. The responsible physician tended to participate
in telemedicine meetings but not in-person meetings, which
raised the cost but also the value of the telemedicine. It
should also be noted that telemedicine costs may be lower
now than when the study was conducted, with costs of this
study expressed in 1999 SEK. Videoconferencing in
Scotland also saved costs over meeting in person, with 42
patients assessed for HNC using telemedicine (£77/patient)
or face to face (£383) (costing year NR) [24, 64].
3.6 Cost Analyses: Treatment Approaches
As studies of direct medical costs for HNC have found,
treatment comprises a large percentage of the overall costs
of care for patients with this cancer. Reveles et al. [55],
analyzing commercial US insurance claims, calculated that
treatment costs represented 89.3 % of the total cost of care
for SCCHN. In the current review, 21 studies identified
costs related to specific treatment approaches: ten from the
USA [21, 27–31, 33, 43, 44, 56, 61, 81, 82], three from
Canada [14, 23, 62], two from France [12, 77], and one
each from India [67, 93], Thailand [71], Greece [26], Spain
[58], the UK [66], and a multicenter study in Europe [79].
A variety of study designs were used, including database
studies (principally in the US), chart reviews, and ran-
domized trials. Studies describing direct costs for the var-
ious HNC treatment modalities are summarized in Table 2.
3.6.1 Hospitalization
Studies assessing the costs of hospitalization in HNC have
been conducted in Thailand [71], Spain [22], France [63],
the UK [66], and the USA [33, 43, 56]. While it is not
possible to compare these costs across different countries
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Table 2 Cost-comparison and cost-identification analyses within treatment approaches for head and neck cancer





Bodard et al. [12] France Cost of extraoral repositioning system used during surgery NR €50
Cost of intraoral repositioning system used during surgery €30
Hammoudi et al.
[77]





Europe Cost of a positive SLNB pathway result per patient NR €17,186–18,244
Cost of a negative SLNB pathway result per patient €4,715
Cost of a false negative SLNB pathway result per patient €17,834–19,014
Cost of traditional surgical approach for stage II oral tumor per patient €27,515
Cost of traditional surgical approach for stage I oral tumor per patient €15,043–15,378
USA
Gourin et al. [27] USA Mean hospital cost of partial laryngectomy 2009 US$23,623
Mean hospital cost of total laryngectomy/laryngopharyngectomy US$50,980
Mean hospital cost of pedicled or free flap reconstruction US$17,083
Gourin et al. [28] USA Mean hospital cost of partial glossectomy 2009 US$17,410
Mean hospital cost of total glossectomy US$25,990
Mean hospital cost of pharyngectomy US$19,715
Mean hospital cost of mandibulectomy US$19,593
Mean hospital cost of neck dissection US$19,528
Mean hospital cost of pedicled or free flap reconstruction US$17,641
Gourin and Frick
[30]
USA Mean hospital cost of partial laryngectomy 2011 US$30,092
Mean hospital cost of total laryngectomy/laryngopharyngectomy US$37,908
Mean hospital cost of neck dissection US$28,715
Mean hospital cost of pedicled or free flap reconstruction US$30,038
Gourin and Frick
[29]
USA Mean hospital cost of partial glossectomy 2011 US$24,041
Mean hospital cost of total glossectomy US$25,935
Mean hospital cost of laryngectomy US$26,615
Mean hospital cost of tonsillectomy US$13,763
Mean hospital cost of pharyngectomy US$20,824
Mean hospital cost of mandibulectomy US$19,673
Mean hospital cost of neck dissection US$23,341
Mean hospital cost of pedicled or free flap reconstruction US$22,679
Li et al. [43] USA Mean hospital cost of partial glossectomy 2012 US$25,810
Mean hospital cost of total glossectomy US$34,459
Mean hospital cost of mandibulectomy US$32,167
Mean hospital cost of neck dissection US$30,710
Mean hospital cost of pedicled or free flap reconstruction US$31,021
Maddox and
Davies [44]
USA Mean hospital charge for laryngectomy in 1997 2008 US$58,000
Mean hospital charge for laryngectomy in 2008 US$109,000
Richmon et al.
[56]
USA Mean hospital cost of pedicled or free flap reconstruction 2012 US$33,798
Mean hospital cost of transoral robotic surgery US$16,262
Rest of world
Brookes et al. [14] Canada Cost savings of resection with tracheostomy site sutured (vs. not
sutured) per patient
NR C$11,609
Smeele et al. [62] Canada Mean total cost of pectoralis major myocutaneous flap reconstruction NR C$20,400
Mean total cost of free flap reconstruction C$23,600
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and healthcare systems, each study concluded that the
burden of hospitalization costs is high.
The three US studies used the Nationwide Inpatient
Sample database and estimated costs per hospitalization of
approximately US$20–23,000 in 2012 dollars. Hennessey
et al. [33] identified 48,263 patients with surgical hospi-
talizations for HNC recorded in this database and estimated
a mean cost to hospitals of US$22,927 for each hospital-
ization (2012 US$). Major surgical procedures were the
factor most associated with increased costs (US$15,682
increase), followed by multiple comorbidities (US$8,869
increase for three or more) and treatment at a teaching
hospital (US$6,361 increase). Similar costs were calculated
by other studies of patients hospitalized with oral malig-
nancy (US$20,934; 2012 US$) [43], and oropharyngeal
neoplasm (US$20,547; 2012 US$) [56]. In each of these
analyses, costs were derived by applying a cost-to-charge
ratio to hospital charges, which are problematic because
the hospital may be reimbursed amounts that differ greatly
from the amounts the hospital charged for its services [44].
Hospitalizations for forms of HNC also presented large
costs to national health systems in Europe and Thailand. In
the UK, an analysis using the HES database estimated that
payments to NHS hospitals in England for HNC hospital-
izations total approximately £57.1 million annually (cost-
ing year NR). Hospitalizations for oral cavity cancers
totaled £12.5 million for men and £7.6 million for women;
for oropharyngeal cancers, costs were £13.3 million for
men and £4.3 million for women; and for laryngeal can-
cers, costs were £16.2 million for men and £3.2 million for
women [66]. A study using the French national hospital
database reported that, in 2007, hospitalizations for HNC
cost €323 million, or €2,764–7,673 per patient. Interest-
ingly, the authors attributed €138 million of this cost to the
Table 2 continued





Razfar et al. [82] USA Cost of IMRT for oral pharyngeal cancer per patient NR US$165,537
Cost of traditional XRT for oral pharyngeal cancer per patient US$87,922
Cost of IMRT for early stage cancer per patient US$97,563
Cost of traditional XRT for early stage cancer per patient US$63,374
Cost of surgery for early stage cancer per patient US$61,265
Cost of IMRT for advanced stage cancer per patient US$52,034
Cost of traditional XRT for advanced stage cancer per patient US$78,046
Sheets et al. [61] USA Total cost of IMRT (vs. CRT) per patient NR US$5,881
Pretreatment cost of IMRT (vs. CRT) per patient -US$1,700
Cost during treatment of IMRT (vs. CRT) per patient US$4,768
Follow-up cost of IMRT (vs. CRT) per patient US$2,288
Rest of world
Donato et al. [23] Canada Costs for immobilization devices used during radiation therapy for the
Uvex system
2004 C$141







Greece Cost of PGEM chemotherapy per patient 2005 €7,419
Cost of PPLD chemotherapy per patient €11,068
Greskovich et al.
[31]




USA Cost of TPF induction added to platinum chemoradiation per patient NR US$189,321
Cost of platinum chemoradiation without TPF induction per patient US$150,270
C$ Canadian dollars, CRT chemoradiotherapy, IMRT intensity-modulated radiotherapy, NR not reported, PGEM pegylated gemcitabine, PPLD
pegylated liposomal doxorubicin, SLNB sentinel lymph node biopsy, TPF docetaxel/cisplatin/5-fluorouracil, US$ US dollars, XRT external beam
radiotherapy
a Abstract reports costs in dollars but does not specify type of dollar
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26 % of HNC caused by HPV infections [63]. A retro-
spective study of patients treated for glottic cancer in Spain
found that mean hospital costs per day were €600–700
(costing year NR) [22]. While the vast majority of database
studies are done in Western countries, a study using
national health data in Thailand reported that, in 2010,
hospital charges totaled 691 million Thai baht (THB) (at
the time, US$21.8 million), or THB26,556 (US$838) for
each of the 26,012 admissions for diagnosis and treatment
of HNC [71].
3.6.2 Surgery
A set of 14 studies widely variable in design, geography,
procedure assessed, and type of disease evaluated costs of
surgery for HNC. Nine studies in the USA, two in Canada,
two in France, two in Spain, and one across Europe
assessed costs of different surgical approaches for HNC
[12, 14, 22, 27–30, 43, 44, 56, 58, 62, 77, 79].
Transoral approaches were judged to be less expensive
than traditional approaches in studies conducted in Spain,
France, and the USA. In Spain, transoral carbon dioxide
laser cordectomy was found to be much less costly
(€2,290) than laryngofissure cordectomy (€13,230) (cost-
ing year NR) [22] in treating patients with glottic cancer. A
retrospective study of 21 patients with an SCC of the upper
aero-digestive tract treated at a French hospital found that
transoral robotic surgery (TORS) was significantly less
expensive than conventional surgery, requiring fewer tra-
cheotomies, shortening stays, and saving $7,134 (specific
currency not reported) [77]. Similarly, a US study of 9,601
patients with oropharyngeal neoplasms reported that use of
TORS resulted in mean per patient savings of US$4,285
(2012 US$) [56].
Other surgical innovations designed as less invasive
may or may not save costs. Maddox and Davies [44], using
a database that samples US hospital discharges, determined
that mean hospital charges for laryngectomies grew from
approximately US$58,000 in 1997 to US$109,000 in 2008
(2008 US$). However, the rise in charges was accompanied
by a rise in larynx-sparing approaches, with the number of
laryngectomies falling by nearly half over the same period
[44]. O’Connor et al. [79], using data from three centers
participating in the European Sentinel Node Trial (SENT)
for early oral SCC, estimated that the sentinel lymph node
biopsy pathway costs approximately 34–56 % of a tradi-
tional surgical pathway. The authors calculated that the
latter treatment costs €15,043–15,378 for a stage I tumor,
and €27,515 for a stage II tumor (costing year NR). In both
a Canadian and a Spanish study, minimal cost difference
was reported between two types of surgical reconstruction.
In the Spanish study of 60 patients undergoing oral cavity
reconstruction following tumor resection, total costs within
the first year of treatment were similar for microvascular
tissue transfer and for use of local or regional flaps; both
costs were approximately €50,000 (costing year NR) [58].
Similarly, the Canadian study of patients with oral or
oropharyngeal cancer found that free flap (C$23,600) and
pedicled flap (C$20,400) surgery had comparable costs
[62]. These costs are likely to vary by the location of the
cancer; three US studies using the National Inpatient
Sample database found that costs for pedicled or free flap
reconstruction ranged from US$10,087 (2012 US$) for
patients with an oral malignancy to US$22,679 (2011 US$)
for HNC patients with any oropharyngeal cancer [29, 43,
56].
3.6.3 Radiotherapy
The costs of radiotherapy have been evaluated in three
studies; a chart review and a database study from the US
reported greater costs of IMRT compared with conven-
tional radiotherapy [61, 82], and a trial from Canada [23]
assessed the costs of immobilization systems used during
this form of treatment.
Several different radiotherapy approaches are utilized in
the treatment of HNC. Conventional radiotherapy generally
involves external beam radiotherapy; more recently,
brachytherapy also is used, frequently as a boost treatment.
Furthermore, IMRT is a newer form of radiation therapy
intended to reduce its toxic effects, but its cost effective-
ness has remained unclear [82]. Sheets et al. [61], using
charts from 194 patients treated with radiation for SCCHN
in a US hospital, calculated that IMRT was associated with
significantly higher total (US$5,881 increase) and treat-
ment (US$4,768 increase) costs than conventional radio-
therapy (costing year NR). However, pretreatment costs
were US$1,700 lower with IMRT, and there was no dif-
ference in follow-up costs. Costs also increased with use of
PET scans, recurrent disease, and patient comorbidities.
Razfar et al. [82], using linked SEER–Medicare data, also
compared IMRT with conventional radiotherapy and esti-
mated that for oropharyngeal cancer, patients receiving
IMRT cost Medicare US$165,537, versus US$87,922 for
conventional radiotherapy (costing year NR). Early stage
cancer treated with single modality therapy resulted in
costs of US$97,563 for IMRT and US$63,374 for external
beam radiotherapy. For advanced disease patients treated
with surgery and radiation, IMRT cost US$78,046 and
conventional radiotherapy US$52,034. Because of the
expense but potential for lower morbidity with IMRT, both
Sheets et al. and Razfar et al. [61, 82] recommend cost-
effectiveness modeling as the next step in these
comparisons.
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3.6.4 Systemic Therapy
Two US studies [21, 31] and one from Greece [26]
examined the costs of chemotherapy associated with cer-
tain combinations or settings. Crandley et al. [21] studied
65 consecutive patients treated at a US oncology center for
oropharyngeal SCC, and reported that they incurred sig-
nificantly higher charges to the hospital if docetaxel/cis-
platin/5-fluorouracil (TPF) induction was added to their
platinum chemoradiation (US$189,321 with induction vs.
US$150,270 without it; costing year NR). A US trial ran-
domized non-nasopharyngeal SCCHN patients to either
inpatient or outpatient cisplatin, and recorded US$18,664
higher costs over 6 months with inpatient administration
(costing year NR) [31]. In Greece, a trial randomized 166
patients to one of two paclitaxel combinations, either with
pegylated liposomal doxorubicin (PPLD) or gemcitabine
(PGEM); PGEM cost significantly less (€7,419) than PPLD
(€11,068) (2005 €) [26].
3.6.5 Multimodal Comparisons
Studies comparing costs among different modes of treat-
ment examined patients in the USA, Spain, the Nether-
lands, Germany, and India. A study by Razfar et al. [81]
using linked SEER–Medicare data evaluated per-patient
costs associated with different multimodal treatment
approaches, finding that surgery is significantly less
expensive than radiation therapy with or without chemo-
therapy. Among 323 patients with T1–T3 laryngeal carci-
noma, costs to Medicare of primary surgery totaled
US$50,444, significantly less than the US$96,271 for
conventional radiation therapy (costing year NR). In turn,
conventional radiotherapy was much less expensive than
IMRT (US$199,661), and having no chemotherapy in the
treatment regimen cost significantly less than including
chemotherapy treatment (US$64,512 vs. US$233,582).
Treatment with both IMRT and chemotherapy cost Medi-
care US$334,754, compared with US$146,442 for patients
receiving other treatment. As above, with comparisons of
IMRT versus conventional radiation, cost-effectiveness
modeling is warranted to further understand whether
potential lower morbidity with radiation instead of surgery
is worth the increased costs [81].
In contrast to the US data, surgery was considerably
more expensive than radiotherapy with or without che-
motherapy in analyses conducted in the Netherlands,
Germany, and Spain. In the Spanish study, laryngofissure
cordectomy (€13,230) was more than double the cost of
radiotherapy (€4,805) (costing year NR) [22]. Similarly, in
the Dutch study, in which costs of diagnosis, treatment,
follow-up, and complications were considered, surgery was
associated with greater costs than radiotherapy, largely
driven by an increase in the number of inpatient days. The
total mean cost per surviving disease-free patient after
1 year was €18,674 for external beam radiotherapy,
€15,101 for brachytherapy, and €25,288 for surgery (2001
€) [46]. In addition, in Germany, costs for primary radio-
therapy (€1,773) or CRT (€2,233) were minimal when
compared with simple (€8,814) or elaborate (€22,298)
surgery (2006 €) [52].
An attempt in rural India to determine whether multi-
modal therapy is feasible in that country, let alone cost
effective, found that basic approaches may be possible [67,
93]. Most of the 230 patients presented to the cancer clinic
with advanced disease and received multimodality treat-
ment. Single modality treatment cost approximately 40,000
Indian rupees (INR), and multimodality treatment
INR80,000 (costing year NR) [67, 93].
3.7 Cost Analyses: Treatment-Related Complications
In the current review, 20 publications from 19 studies
described costs attributable to symptoms and side effects
arising directly from the various treatments for HNC [11,
13, 15, 16, 25, 32, 36, 39, 42, 45, 47, 49, 50, 54, 59, 60, 73,
75, 76, 94]. The most commonly reported costs for treat-
ment-related complications were due to infection [15, 16,
39, 45, 49, 59, 73] and surgical reconstruction following
tumor resection [11, 36, 60, 75, 94]. Expenses for several
other treatment-emergent side effects were noted, including
peripheral neuropathy [50], dermatologic adverse drug
reactions, acute mucositis [13, 25, 47, 54], osteoradione-
crosis [76], and deep vein thrombosis or pulmonary
embolism [32]. The majority of these studies (n = 12)
evaluated economic data in the USA, and one economic
analysis each was performed in the Netherlands [13],
Canada [76], Finland [60], France [49], Ireland [73], and
Taiwan [16].
3.7.1 Surgical Interventions
Four retrospective chart reviews, three conducted in the
USA [11, 36, 75, 94] and one in Finland [60], assessed the
costs of microsurgical free flap reconstruction in HNC and
found that post-surgical or medical complications drive
higher costs, especially in older patients and those who stay
longer in an intensive care unit (ICU). A US study of 114
HNC patients reported that the average total cost of free
flap surgical therapy was considerably greater (US$54,702)
for octogenarian patients compared with younger counter-
parts (US$30,397) (costing year NR) [94]. This increase in
cost largely resulted from greater pre-operative morbidity
among the octogenarians, which more than quadrupled
medical complications in this group (62 % of patients)
compared with the younger patients (15 %). Increased
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costs due to post-surgical complications also were identi-
fied in a study of 100 US HNC patients having microsur-
gical reconstruction. The average hospital length of stay
nearly doubled for patients who experienced post-surgical
complications, resulting in a 70.7 % increase (US$20,292)
in true costs compared with patients without additional
complications. ICU costs (US$1,956) accounted for a large
component of this increased expenditure, especially in
association with post-surgical complications (US$9,760)
[36]. Furthermore, a US study of 257 HNC patients who
had undergone free flap surgery found that average cost per
patient was increased by US$3,238 when patients were
cared for in the ICU versus a non-ICU setting following
surgery [11, 75]. In the Finnish study, surgical complica-
tions nearly doubled costs, although this study only
reported cost data separately for HNC patients in its
abstract, limiting interpretation of the data [60].
3.7.2 Systemic Therapy
Two large US commercial database studies evaluated
chemotherapy-associated peripheral neuropathy [50] and
chemotherapy-related dermatologic side effects [54] and
found that both conditions are associated with substantial
economic burden. An analysis of a US commercial data-
base reported that, compared with demographically mat-
ched controls without peripheral neuropathy, HNC patients
with peripheral neuropathy have excess annual per patient
healthcare costs of US$36,660 (2006 US$) [50]. Similarly,
an analysis of another commercial database (2000–2010
US$) identified higher costs for cetuximab-treated HNC
patients who had experienced a dermatologic side effect
(n = 333) versus those who had not (n = 638). Patients
with a skin-related side effect incurred average monthly
total healthcare costs of US$12,539; those without a der-
matologic side effect had costs of US$9,684 (2010 US$)
[54]. After controlling for confounding factors, patients
with skin-related side effects incurred a significant incre-
mental total healthcare cost of US$2,284 per patient per
month, mainly due to an incremental inpatient cost of
US$1,702 per patient per month for those experiencing a
dermatologic side effect.
3.7.3 Radiotherapy or Combined Chemoradiotherapy
A Dutch randomized controlled trial (RCT) [13], a Cana-
dian retrospective chart review [76], and a US retrospective
cohort database study [42] reported that costs associated
with treatment-emergent side effects of radiotherapy or
combined chemoradiotherapy (CRT) were considerable,
and were driven in a large part by inpatient hospital
admissions. Lang et al. [42] determined that mean per-
patient costs associated with treatment-related side effects
were significantly higher for patients who received CRT
(US$15,825) than among those treated with radiotherapy
alone (US$6,223) (2006 US$). Expenses for treatment-
related side effects represented 17 % of total costs of
treatment for patients who received combination therapy
and 11 % of costs for those who received radiotherapy
only, with hospital inpatient expenses comprising the
largest cost component in both groups. Similarly, in the
Dutch RCT, hospital admissions accounted for the majority
(€3,013) of total average costs associated with chemora-
diation toxicity (€3,789) [13]. The Canadian study specif-
ically examined costs of surgical treatment of
osteoradionecrosis of the mandible as a treatment-related
side effect of radiotherapy in HNC patients. In this eval-
uation of 13 patients, the average cost per admission was
C$12,929, and total healthcare expenditure (16 admissions)
was C$206,860 [76].
Acute oral mucositis as a side effect of radiotherapy or
radiochemotherapy was evaluated separately from other
treatment-related complications in two US retrospective
cohort studies, both of which determined that medical costs
were higher for HNC patients who developed severe mu-
cositis than for those who did not. In a US study of 204
patients, costs of oral mucositis increased with more severe
disease; incremental costs were US$1,700 for patients with
grade 1–2, and US$3,600 for patients with grade 3–4 oral
mucositis (2006 US$) [25]. Higher costs were reported in a
US study of 99 HNC patients, 70.1 % of whom experi-
enced severe mucositis/pharyngitis during radiochemo-
therapy. Incremental inpatient hospital costs for these
patients were US$14,000 and total medical costs were
US$17,244 (2005 US$) [47].
3.7.4 Infection
Several studies in multiple countries examined costs due to
infectious complications of treatment for HNC, including
pneumonia and catheter-associated infection; all types of
infection increased medical costs. A large US public
database study found that for 123,662 HNC patients, vas-
cular catheter-associated infection, while a rare complica-
tion, accounted for [70 % of all hospital-acquired
conditions [39]. These infections accounted for a mean
increase in surgical costs of US$22,757 (2012 US$). In
addition, a recent cross-sectional study of 93,633 HNC
patients treated surgically in the USA found that after
controlling for other variables, urinary tract infection
associated with peri-operative urinary catheterization sig-
nificantly increased length of hospitalization and related
costs (US$14,992 increase) [15]. Similarly, a study of US
Medicare claims data for HNC patients aged 65 years and
older reported that serious fungal infections during hospi-
talization resulted in higher Medicare payments
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(US$25,942) for affected patients than for those without
this condition (US$10,131) (1998 US$) [45]. It should be
noted that lower reported costs in this latter study com-
pared with others included in this review likely reflect the
older costing year (1998), and the rising costs of healthcare
in the intervening 15 years.
Post-treatment pneumonia was associated with
increased medical costs in studies conducted in France,
Taiwan, and the USA [16, 49, 59]. In the French pro-
spective cohort study, post-operative pneumonia added
€19,000 of direct medical costs to treatment. Patients who
developed both surgical site infection and post-operative
pneumonia had additional costs of €35,000 (2005 €) [49].
Similarly, in a retrospective claims analysis using Taiwan’s
National Health Insurance database, HNC patients with
pneumonia following radiotherapy incurred an additional
US$11,612 in overall medical costs (approximately
US$188/day) (costing year NR) [16]. In addition, a large
US database study concluded that infectious pneumonia
increased hospital costs by US$17,095, while aspiration
pneumonia raised costs by US$12,510 (2011 US$) for
HNC patients who developed these conditions [59].
Costs of antibiotic use to treat or prevent post-operative
infection in HNC patients were assessed in two studies. A
prospective study of 50 HNC patients in India reported that
mean costs for use of a single antibiotic for prophylaxis
were INR803, while those for use of combination antibiotic
therapy were INR1,524 (costing year NR). Total cost for
prophylaxis and post-operative treatment with antibiotics
did not differ between the two regimens [48]. In a chart
review of hospital data in Ireland, costs of the first hospital
stay were more than three times higher in methicillin-
resistant Staphylococcus aureus (MRSA)-positive patients
than in MRSA-negative patients. Antibiotic costs were
increased by 2,470 Irish pounds for HNC surgical patients
treated for MRSA infection (costing year NR) [73].
3.8 Cost Analyses: Supportive and Palliative Care
Six studies in the USA, Korea, the Netherlands, and Aus-
tralia [18, 19, 38, 41, 55, 57, 70] have examined costs
associated with interventions related to nutritional support,
post-treatment surveillance, and hospice or end-of-life care
in HNC patients. Direct costs of these types of supportive
and palliative care are minimal when compared with costs
of treatment and expenditures for treatment-related side
effects. However, it should be noted that there are no
studies on palliative radiation, which may have higher costs
than other forms of supportive care.
Two US database studies assessed supportive and pal-
liative care incremental costs using Medicare claims data
comparing HNC patients to demographically matched
cancer-free controls [38, 41]. A high proportion of patients
with metastatic HNC (90.2 %) or recurrent HNC (71.0 %)
received supportive care. For metastatic HNC patients,
supportive care costs were US$1,136 versus US$20 in
controls; for recurrent HNC patients, supportive care costs
were lower (US$342) than for metastatic HNC, but
remained considerably higher than those for cancer-free
controls (US$24) (2008 US$) [38]. Similarly, while only
14 % of HNC patients utilized hospice care, mean pay-
ments for this care were significantly higher for patients
(US$899) than for controls (US$120) (1998 US$) [41].
Costs of end-of-life care for HNC patients were further
analyzed in a study of a US commercial claims database.
These costs were assessed for patients diagnosed with
advanced HNC between March 2003 and March 2008,
comparing costs for the period prior to and following
approval of cetuximab. Costs for end-of-life care were
similar (US$15,853 prior to approval, US$21,822 follow-
ing approval) for both groups [55].
An Australian RCT and a Korean RCT compared costs
of two methods of providing nutritional support to HNC
patients undergoing CRT or surgery; in both trials, naso-
gastric tube feeding was the less costly option. In the
Australian trial, percutaneous endoscopic gastrostomy
(PEG) tubes were nearly tenfold more costly than naso-
gastric tubes for nutritional support. This study examined
32 patients treated with PEG tubes and 73 with nasogastric
tubes; the cost for PEG tubes was A$736, while cost for
nasogastric tubes was A$76 (costing year NR) [18, 19].
The Korean trial compared nasogastric tube nutrition with
total parenteral nutrition (TPN); the latter cost 11,810
Korean won (KRW) more per day. In addition, the initial
device cost was more than tenfold higher for a central
venous catheter for TPN (KRW24,210) than for a naso-
gastric tube (KRW3,510) (2007 KRW) [57].
A study of post-treatment surveillance in the Nether-
lands of patients with suspected recurrence of laryngeal
cancer following radiotherapy found that 18F-deoxyglucose
positron emission tomography (FDG-PET) scans resulted
in cost savings over a direct laryngoscopy strategy. Using
the results of the FDG-PET scan to select patients for
laryngoscopy rather than performing this procedure on all
patients led to mean cost savings of €399 (2003 €) with
similar clinical outcomes [70].
3.9 Indirect Costs of HNC
Four studies identified by the current review reported high
indirect costs associated with HNC [17, 65, 74, 80], par-
ticularly for the cost of patient time reduced workforce
participation. A US study assessing the indirect costs of
laryngeal cancer over a 12-month period found that each
patient missed a mean 98 days from work. For the 35
patients assessed, short-term disability payments totaled
Economic Burden of HNC: A Systematic Literature Review 877
US$361,730, and total lost wages in the 1-year period
US$556,955 (2008 US$) [17]. A study using Norwegian
population data to assess the impact of cancer on
employment and earnings reported that HNC significantly
lowered the odds of employment for men and women. It
also significantly reduced earnings compared with the
reference cancer-free population, by 17 % for men and
16.1 % for women [65]. Survey data collected from indi-
viduals with HNC in Ireland were combined with popula-
tion-level survival estimates and national wage data to
estimate the indirect costs associated with the disease. The
average productivity losses per person attributable to
temporary and permanent work absence and reduced work
hours totaled €222,000 [80]. A US study of national patient
time costs for HNC patients aged 65 years and older esti-
mated that these costs in 2005 reached US$101,187 [74].
For the initial phase of care, net patient time costs were
US$1,679 for hospitalizations, US$146 for ambulatory
physician visits, and US$443–2,268 for other services
(costing year NR). These costs tended to increase during
the patients’ last year of life, especially for hospitalizations
[74].
4 Discussion
Studies assessing the full societal burden of HNC were not
identified by this review; however, individual studies of
overall national direct and indirect costs in the USA [85,
86] and in France [87] suggest that these components
contribute nearly equally to the overall burden of disease.
Very few studies reporting indirect costs of HNC were
captured in this review, but of the four available, HNC
appears to cause substantial work loss in the USA, Norway,
and Ireland [17, 65, 74, 80]. Studies of direct medical costs
of HNC have been dominated by US database studies,
albeit with substantial heterogeneity in data sources and
study designs that tends to thwart comparisons. Costs in
linked SEER–Medicare data reflect the perspective of this
US government program for insuring the elderly, who may
have different costs and disease manifestations than
working-age populations whose care is recorded in dat-
abases from private insurers. Given additional differences
in time horizons (e.g., 6 months in one study, 5 years in
another) as well as disease subpopulations (early disease in
one study, metastatic HNC in another) and dates of diag-
nosis (the early 1990s in one study, the mid-2000s in
another), it becomes impossible to compare or pool mul-
tiple studies to support a single estimate of a cost.
However, a clear general picture can emerge from the
totality of the evidence, showing that this cancer presents a
large economic burden to private and public payers in the
USA, and from a smaller number of studies, payers in
Europe and elsewhere. More work is needed outside the
USA, but in Europe and other regions, it is harder to find
databases that are available to commercial sponsors of
health economic research. Prospective studies would be a
good alternative, and not many have been published in
HNC. This has not changed since the review of the eco-
nomics of HNC published in 2004 by Lee et al. [95], who
noted a plethora of cost identification studies but very few
with a prospective design. Adding economic endpoints to
trials enrolling head and neck patients would be a good
tack to take in any region. From the evidence currently
available from the UK [37] and the Netherlands [69], forms
of HNC present very high direct costs to these healthcare
systems. It may be informative for future studies in Europe
to focus on the costs of surgery; in contrast to the USA,
surgical treatment appears substantially more expensive
than radiotherapy with or without chemotherapy [22, 46,
52].
4.1 Low-Morbidity Techniques May Not Save Costs
In the USA, trends away from surgery may avoid associ-
ated morbidity, and the same is true for IMRT instead of
conventional radiotherapy. However, these noninvasive/
low-toxicity approaches do not necessarily lower total
costs. A comparison in linked SEER–Medicare data by
Razfar et al. [81] of surgery, radiation (IMRT or conven-
tional), and chemotherapy found that for T1–T3 laryngeal
carcinoma, surgery cost significantly less than any of the
other modalities. Razfar et al. [82] also compared IMRT
with conventional radiotherapy, as did Sheets et al. [61],
and found significantly higher costs with IMRT. Cost-
effectiveness modeling is needed to determine the value in
quality-adjusted time of the added costs of these lower-
morbidity approaches to HNC treatment. A recent German
model determined that induction chemotherapy is cost
effective in the treatment of operable advanced HNC [96];
similar strategies could be applied to analysis of other
treatment options. In Europe, with surgery both more
expensive and invasive than radiotherapy and chemother-
apy, modeling should investigate whether its efficacy off-
sets these disadvantages.
4.2 Some HNC Costs to US Payers Have Risen
Over the Last Decade
Some, but not all, costs of HNC appear to have risen over
time in the USA. In a study by Reveles et al. [55] using
commercial insurance claims, median total costs did not
differ significantly between a cohort diagnosed with
advanced SCCHN in 2003–2006 and a cohort diagnosed in
2006–2008. However, diagnostic costs rose significantly
after 2006. Maddox and Davies [44], using a database of
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US hospital discharges, calculated that mean hospital
charges per patient for laryngectomies nearly doubled from
1997 to 2008 in constant 2008 dollars. However, a trend
toward less use of surgery over the same period meant that
only half as many laryngectomies were performed in 2008
compared with 1997. These types of large, structural
changes in healthcare delivery may contribute to the recent
slowdown in US spending on healthcare, which at present
is only rising at approximately the rate of inflation.
Spending is currently forecast to increase in 2014 and
beyond with an aging population, an improved economy,
and passage of the Affordable Care Act [97].
4.3 Limitations
Chief among the limitations of the current review is that it
includes only studies that assessed and reported original
costs. It therefore omits nearly all models and systematic
reviews, which use secondary cost data. Studies reporting
original data are usually retrospective database analyses,
especially in the USA, so it is also important to note that
databases are not a good source of information about tumor
stage and location. For analyses of the influence of stage
and location on cost, chart reviews will be more likely to
yield usable information. Other limitations of the current
review are that it is limited to English-language literature,
and that it omits US studies of real-world cetuximab costs
for late stage HNC, as the 2011 approval of cetuximab for
metastatic/recurrent HNC in the USA would have been too
recent for even 2013 publications to have assessed an
adequate sample and timeframe.
4.4 Next Steps
The best next step would be to review models and other
studies using secondary data, identify gaps in understand-
ing of both original and modeled economic burden, and
then use the current review of original costs to derive data
for the next set of models. This would include published
data but also identification of databases that have yielded
sufficient cost information regarding this cancer. A new
look at databases or charts, especially in Europe or other
areas outside the USA, will also yield retrospective data on
costs of recent developments such as cetuximab, as well as
HPV vaccines [98]. Because this review is limited by the
fact that approximately 90 % of reviewed studies do not
report cost data by HNC tumor site, and even fewer report
cost data by tumor stage, we recommend that (as possible)
future analyses consider reporting care and associated costs
by specific HNC tumor site as well as by tumor stage.
Taken together, these efforts to gain a greater under-
standing of the economic burden of this cancer will
improve the ability of healthcare systems to prioritize and
select forms of care that are both effective and affordable.
5 Conclusions
Studies have not addressed the societal burden of HNC, but
evidence from the USA and France suggests approximately
equivalent direct and indirect costs to these countries. Most
studies of direct medical costs have used US databases of
claims to public and private payers; in the USA, excess
costs to these payers were estimated to be US$8.5 billion in
2008. In the UK, costs to the NHS totaled £255 million
over a possible 5 years following resection. Costs appear
higher for patients with metastatic/recurrent disease, those
undergoing surgery and during the first year afterward, and
US patients insured by private payers. Indirect costs mea-
sured in the USA, Norway, and Ireland indicate that HNC
causes substantial work loss in these countries. More work
is needed in Europe and other regions outside the USA, in
addition to prospective cost-identification studies and
evaluations of the costs of surgery in Europe.
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